Evidence map›Paper›PMID 36935498›Full record

ArticleJournal of cheminformatics2023

PROTEOMAS: a workflow enabling harmonized proteomic meta-analysis and proteomic signature mapping.

Aileen Bahl, Celine Ibrahim, Kristina Plate, Andrea Haase, Jörn Dengjel, Penny Nymark, Verónica I Dumit

Full text read
In one paragraph

Article in Journal of cheminformatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Environmental science. Nano · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aileen BahlDepartment of Chemicals and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.
Celine IbrahimDepartment of Chemicals and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.
Kristina PlateDepartment of Chemicals and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.
Andrea HaaseDepartment of Chemicals and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.
Jörn DengjelUniversity of Fribourg, Fribourg, Switzerland.
Penny NymarkInstitute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden.
Verónica I DumitDepartment of Chemicals and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany. Veronica.Dumit@bfr.bund.de.

Funding

BfR Sonderforschungsprojekt 1322-777EU H2020 project NanoInformaTIX No 814426Swedish Fund for Research Without Animal Experiments F2021-0005Swiss National Science Foundation, NRP79 "Advancing 3R - Animals, Research and Society", by the canton and the University of Fribourg, and by the SKINTEGRITY.CH 407940
6 · The paper itself

Abstract

Toxicological evaluation of substances in regulation still often relies on animal experiments. Understanding the substances' mode-of-action is crucial to develop alternative test strategies. Omics methods are promising tools to achieve this goal. Until now, most attention was focused on transcriptomics, while proteomics is not yet routinely applied in toxicology despite the large number of datasets available in public repositories. Exploiting the full potential of these datasets is hampered by differences in measurement procedures and follow-up data processing. Here we present the tool PROTEOMAS, which allows meta-analysis of proteomic data from public origin. The workflow was designed for analyzing proteomic studies in a harmonized way and to ensure transparency in the analysis of proteomic data for regulatory purposes. It agrees with the Omics Reporting Framework guidelines of the OECD with the intention to integrate proteomics to other omic methods in regulatory toxicology. The overarching aim is to contribute to the development of AOPs and to understand the mode of action of substances. To demonstrate the robustness and reliability of our workflow we compared our results to those of the original studies. As a case study, we performed a meta-analysis of 25 proteomic datasets to investigate the toxicological effects of nanomaterials at the lung level. PROTEOMAS is an important contribution to the development of alternative test strategies enabling robust meta-analysis of proteomic data. This workflow commits to the FAIR principles (Findable, Accessible, Interoperable and Reusable) of computational protocols.

Indexed as

Adverse outcome pathways (AOP)FAIR dataHarmonized proteomics data analysisMeta-analysisMode-of-action (MoA)NanomaterialsProteomics

Identifiers

PMID36935498
PMCPMC10024914

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read10
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.